Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Posted: April 21, 2025 at 2:44 am

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo

Original post:
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Related Posts